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Abstract
Objective To assess risks of mortality associated with use of individual
antipsychotic drugs in elderly residents in nursing homes.
Design Population based cohort study with linked data from Medicaid,
Medicare, the Minimum Data Set, the National Death Index, and a
national assessment of nursing home quality.
Setting Nursing homes in the United States.
Participants 75 445 new users of antipsychotic drugs (haloperidol,
aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone). All
participants were aged ≥65, were eligible for Medicaid, and lived in a
nursing home in 2001-5.
Main outcome measures Cox proportional hazards models were used
to compare 180 day risks of all cause and cause specific mortality by
individual drug, with propensity score adjustment to control for potential
confounders.
Results Compared with risperidone, users of haloperidol had an
increased risk of mortality (hazard ratio 2.07, 95% confidence interval
1.89 to 2.26) and users of quetiapine a decreased risk (0.81, 0.75 to
0.88). The effects were strongest shortly after the start of treatment,
remained after adjustment for dose, and were seen for all causes of
death examined. No clinically meaningful differences were observed for
the other drugs. There was no evidence that the effect measure
modification in those with dementia or behavioural disturbances. There
was a dose-response relation for all drugs except quetiapine.
Conclusions Though these findings cannot prove causality, and we
cannot rule out the possibility of residual confounding, they provide more
evidence of the risk of using these drugs in older patients, reinforcing
the concept that they should not be used in the absence of clear need.
The data suggest that the risk of mortality with these drugs is generally
increased with higher doses and seems to be highest for haloperidol
and least for quetiapine.
Introduction
Up to a third of all elderly patients in nursing homes are treated
withantipsychoticdrugs.
1-5Inthepast,inappropriateprescribing
of antipsychotics in nursing homes has primarily been
considered a marker of suboptimal care.
6 7 Federal action thus
focusedprimarilyondefiningandenforcingspecificdiagnostic
criteriafortheinitiationandmonitoringofthesedrugs(Omnibus
Budget Reconciliation Act).
8 In recent years, evidence has
accumulated that their use is a drug safety issue as well. After
earlier warnings of increased risks of cerebrovascular events
(with risperidone, olanzapine, and aripiprazole),
9 the Food and
Drug Administration issued an advisory warning in 2005 that
atypicalantipsychoticswereassociatedwitha60-70%increased
risk of death compared with placebo in randomised controlled
trials among older patients with dementia, and black box
warnings were added to the labels of all atypical drugs.
10
Subsequent studies found risks at least as high among users of
conventional antipsychotics,
11-13 and the Food and Drug
Administrationissuedasimilarwarningforsuchdrugsin2008.
14
Despitethesestrongsafetywarnings,useofantipsychoticdrugs
in nursing homes is likely to remain substantial—as evidenced
bytherecentauditbytheUSDepartmentofHealthandHuman
Services
15—because of the continued growth in the number of
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Research
RESEARCHpeople with dementia, the perceived need for some type of
intervention in patients with severe persistent symptoms, and a
paucity of effective alternative pharmacological or behavioural
approaches.
16 Questions about the comparative safety of
individual antipsychotic drugs are therefore of paramount
importance to patients and prescribers, but the existing Food
andDrugAdministrationadvisoriesdonotdistinguishbetween
drugs in these classes and thus offer no guidance in that regard.
Intheabsenceofrandomisedtrials,surveillancedatafromlarge
longitudinal healthcare databases provide a unique opportunity
toexaminethecomparativesafetyofindividualdrugs,provided
thatrigorousmethodologicalapproachesareappliedtominimise
bias.Suchdatabasesalsoincludethemostvulnerablesegments
of the population, such as residents of nursing homes, who are
commonly excluded from trials.
We investigated whether the risk of overall and cause specific
mortality is equal across antipsychotic drugs or whether there
are regimens with safety advantages that should be prescribed
preferentially in older residents of nursing homes.
Methods
Data source and study cohort
ThestudycohortwasdrawnfromamergeddatasetofMedicaid
and Medicare claims, the minimum data set (MDS), the Online
Survey Certification and Reporting (OSCAR) system, and the
NationalDeathIndexin45statesintheUnitedStates(allexcept
Arizona, Delaware, Nevada, Oregon, and Rhode Island) for
2001-5. Claims data provided information on patients’
demographics, eligibility for Medicaid, physician services and
admissions to hospital and their accompanying diagnoses,
admissions to long term care, and filled prescriptions for drugs.
The Minimum Data Set is a federally mandated health
assessmenttoolusedinnursinghomesthatcapturesinformation
onphysical,psychological,andpsychosocialfunctioning,active
clinical diagnoses, health conditions, treatments, and services.
The Online Survey Certification and Reporting system is a
uniform database of nursing home regulatory reviews, which
isgeneratedyearlyforallnursinghomescertifiedbytheCenters
for Medicare and Medicaid Services (CMS) and includes
operational and staffing characteristics and aggregate resident
characteristics.
Our cohort consisted of all patients aged ≥65 who were dually
eligibleforMedicareandMedicaid,whostartedtreatmentwith
an antipsychotic drug during a stay in a nursing home, and who
had six months’ continuous Medicaid coverage before the date
they started the antipsychotic drug (index date). Incident use
required the absence of filled prescriptions for an antipsychotic
in the six months before the index date. We used an incident
user design to avoid underascertainment of events that occur
soon after treatment begins
17 and to ensure that baseline
covariates at study entry were assessed before the start of
treatment and were not affected by the treatment itself.
18
Residents were excluded if they filled a prescription for both
conventional and atypical antipsychotics on the index date and
if they had a pre-existing diagnosis for cancer, schizophrenia,
or bipolar disorder as these residents probably received
antipsychotics for reasons other than behavioural problems
related to dementia (fig 1⇓).
Exposure to antipsychotic drugs
Antipsychotic drugs considered include haloperidol,
aripiprazole, olanzapine, quetiapine, risperidone, and
ziprasidone. Other drugs (thioridazine, chlorpromazine,
perphenazine, fluphenazine, acetophenazine, mesoridazine,
promazine, trifluoperazine, triflupromazine, chlorprothixene,
loxapine,molindone,pimozide,andthiothixene)wereexcluded
because they were used by too few patients (1% for all
combined)topermitinterpretableestimationoftheassociations
between drug and outcome (fig 1⇓). Each participant was
assigned to a specific drug based on the first prescription; a
given exposure was considered as discontinued if there was a
gap in treatment of 14 days or more. We chose the most
commonly used drug in this population, risperidone, as the
reference drug. We converted daily doses of the index drug to
equivalent doses of chlorpromazine (in mg)
19-21 and used the
mediandailydoseinthepopulation(50mg)asacutofftoassess
the effect in groups of higher and lower doses (see table A in
appendix on bmj.com). In dose-response analyses, we
empirically defined cut offs for low, medium, and high dose
groups for each individual drug after inspection of the dose
distributions (see table B in appendix on bmj.com).
Outcomes
Information on vital status and causes of death was available
through linkage with the National Death Index. We identified
alldeathsinthecohortwithin180daysaftertheindexdate.We
excluded deaths from cancer because such cancers were
probably pre-existing and might have been associated with use
of some drugs in this class to reduce nausea or to potentiate
drugs for pain relief. As we recognise the potential for
misclassification of causes of death in older populations,
22 we
examined the following groups of causes based on suggested
pharmacological effects of antipsychotics
23-27 and the Food and
Drug Administration analysis
10: diseases of the circulatory
system (ICD-10 (international classification of diseases, 10th
revision) codes I00-I99), cerebrovascular diseases (ICD-10
codesI60-I69),diseasesoftherespiratorysystem(ICD10codes
J00-J99), and all other causes combined.
Characteristics of patients and nursing homes
We assessed characteristics of patients in the six months before
cohort entry. Sociodemographic characteristics included age,
sex, race, education, and geographical region (state). Clinical
characteristics were determined according to the most recent
Minimum Data Set assessment before the start of treatment,
ICD-9 diagnostic and procedure codes associated with
admissions to hospital and visits to physicians, and drug use.
These variables assessed psychiatric morbidity, cardiovascular
morbidity, cerebrovascular disease, Parkinson’s disease,
epilepsy,diabetes,obesity,functionalimpairment,theCharlson
index, and use of healthcare services potentially predictive of
adverse health outcomes in the short term (number of days in
hospital, number of distinct prescriptions for drugs excluding
antipsychotics).
28Weobtainedcharacteristicsofnursinghomes,
which could be correlated with care processes and risk of
adverse health outcomes, from the Online Survey Certification
andReportingsystem.Theseincludedvariablessuchasfacility
size, occupancy rate, availability of special care units, staffing
levels, ownership, resident characteristics (for example,
proportion with dementia, depression) and quality indicators
(for example, proportion bedbound).
Data analysis
We compared distributions of sociodemographic, clinical, and
use characteristics among participants who started taking
differentantipsychoticsandcalculatedratesofmortalityduring
follow-up.Wecensoredfollow-upatthetimeofdiscontinuation
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RESEARCHof treatment, augmentation, or switch to a different drug, and
admission to hospital for 10 days or more, as treatment status
is unknown during inpatient stays. To reduce the potential for
informative censoring, we implemented a 30 day grace period.
All deaths occurring during this time were attributed to the
initial exposure.
Wefittedproportionalhazardsmodelsforpairwisecomparisons
against risperidone (unadjusted; adjusted for age, sex and
calendar year; and adjusted for multiple variables). In
multivariate analyses, we used propensity score adjustment to
balancepotentialconfounders.
29Propensityscoreswerederived
from predicted probabilities of the start of treatment estimated
in logistic regression models that contained all covariates listed
above.Coxmodelswerestratifiedacross10thsofthepropensity
score. In addition, we plotted multivariate adjusted
Kaplan-Meier curves for survival as a function of the duration
of use of the index antipsychotic using inverse probability of
treatment weighting.
30 In confirmatory analyses, we fitted high
dimensional propensity scores,
31 which have been shown to
improve validity in claims data studies by further reducing
residual confounding.
32 33
We ran propensity score and outcome models separately in
groups defined by recorded diagnoses of dementia and
behavioural disturbances and by dose, dividing each group into
those taking ≤50 mg or >50 mg chlorpromazine equivalents a
day. A dose-response analysis was conducted to compare the
risk of deaths from causes other than cancer in residents treated
with high or medium versus low dose antipsychotics, for all
drugs separately and combined. In sensitivity analyses, we
estimated the strength of the residual confounding that would
berequiredtofullyexplaintheobservedassociationsfordeaths
from causes other than cancer if in truth no such associations
existed.
34
Results
From 2001 to 2005, 75 445 older residents of nursing homes
started treatment with antipsychotic drugs. Compared with the
reference group risperidone, patients who started taking
haloperidol were more likely at baseline to have cardiovascular
disease, less likely to have psychiatric comorbidities, and had
slightly worse general indicators of comorbidity. Patients who
startedtakingrisperidonehadslightlyfewerrecordeddiagnoses
of depression and less use of antidepressants and other
psychoactive drugs than patients who started treatment with
other atypical antipsychotics. They also tended to have a lower
useofcholinesteraseinhibitors.Patientstreatedwithquetiapine
had more diagnoses of parkinsonism than the other groups, and
patientstreatedwitholanzapinehadfewerdiagnosesofdiabetes.
There were also some differences in the prescribing of specific
drugs between regions and settings (table 1⇓ and table C in
appendix on bmj.com).
Eighty per cent of residents (n=60 167) were censored before
the end of 180 days. Discontinuation of treatment was the most
common reason for censoring (57.2%, n=34 388), followed by
hospital admission for 10 days or longer (17.4%, n=10 464),
treatmentswitchesoraugmentation(13.1%,n=7902),anddeath
(12.3%, n=7413). A total of 6598 residents died from causes
other than cancer during the first 180 days after the start of
treatment, yielding an event rate of 37.1 per 100 person years
(95% confidence interval 36.2 to 38.0). Table 2 shows event
rates for specific treatments⇓.
All cause mortality
Findings from the Cox regression analyses indicated that,
compared with risperidone, patients treated with haloperidol
had double the risk of mortality (hazard ratio adjusted for
propensity score 2.07, 95% confidence interval 1.89 to 2.26)
and patients treated with quetiapine had a reduced risk (0.81,
0.75 to 0.88). No meaningful differences in risk were observed
foraripiprazole,olanzapine,andziprasidone(table3⇓).Adjusted
Kaplan-Meier plots are consistent with these findings (fig 2⇓).
The effect of haloperidol was strongest during the first 40 days
of treatment (hazard ratio adjusted for propensity score 2.34,
2.11 to 2.60) and reduced to 1.32 (1.02 to 1.71) and 1.46 (1.07
to 2.00) after 40-79 and 80-180 days of treatment, respectively.
The corresponding rate ratios for quetiapine were 0.74 (0.66 to
0.82), 0.87 (0.75 to 1.01), and 0.91 (0.79 to 1.05). Analyses
stratified by dose confirmed the overall findings (figs 3⇓ and
4⇓), and we did not find evidence that the effect measure was
modified by the presence of a recorded diagnosis of dementia
or behavioural disturbances (see table D in appendix on
bmj.com).Sensitivityanalysesindicatedthatforanunmeasured
confounder (such as frailty, severity of dementia) present in
25% of the population, relative risks ≥5.0 linking the
hypothetical confounder to both haloperidol use and mortality
would be needed to fully explain the observed association with
mortality. For confounders present in 10% or 5% of the
population, relative risks of >6.0 and 7.5, respectively, would
be needed. To fully explain the protective association for
quetiapine,relativerisksof>2.5,3.5,and5.0wouldberequired
for an unmeasured confounder present in 25%, 10%, and 5%,
respectively, of the population (see figs A and B in appendix
on bmj.com).
Cause specific mortality
Almost half (49%, n=3262) of deaths were recorded as caused
by circulatory disorders, 10% (n=655) by cerebrovascular
diseases, and 15% (n=981) by respiratory disorders. Table 2
shows the cause specific event rates by treatment group⇓. The
increased risk of death with haloperidol and the decreased risk
with quetiapine were observed for all causes examined.
Although no difference in overall mortality was observed for
olanzapine,findingssuggestapossiblylowerriskofdeathfrom
cerebrovascular diseases (hazard ratio adjusted for propensity
score 0.88, 0.73 to 1.07; hazard ratio adjusted for high
dimensional propensity score 0.83, 0.68 to 1.01). Given the
relativelysmallnumberofpatientstreatedwitharipiprazoleand
ziprasidone, the associations for cause specific mortality are
imprecisely estimated (table 3⇓).
Whenwecomparedtheriskofalldeathsfromcausesotherthan
cancer in residents treated with high versus low and medium
versus low dose of a given drug, our findings suggest a
dose-response relation for all antipsychotic drugs except
quetiapine (fig 4⇓). The dose effects were most pronounced for
haloperidol (hazard ratio adjusted for propensity score 1.84 for
high and 1.40 for medium dose, both compared with low dose)
and for risperidone (1.35 for high and 1.19 for medium dose).
Discussion
Summary of main findings
In elderly residents receiving antipsychotic drugs in nursing
homes, there is variation in the risk of death according to the
typeofdrugused.Comparedwithrisperidoneusers,haloperidol
usershadanincreasedriskandquetiapineusershadadecreased
riskofdyingwithin180days.Theeffectswerestrongestshortly
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RESEARCHafter the start of treatment and remained after adjustment for
dose. No clinically meaningful differences were observed for
theotherdrugs.Therewasnoevidencethatthetreatmenteffect
differedforpatientswithadiagnosisofdementiaorbehavioural
disturbances. A dose-response relation was observed for all
drugs, except quetiapine. The study was carried out in 75 445
residents of nursing homes in 45 states in the US. All
participantswereaged≥65,startedtreatmentwithantipsychotic
drugs between 2001 and 2005, and were eligible for Medicaid.
Results in context
Our results for haloperidol are consistent with the findings of
observational studies that report a greater risk of death with
conventionalversusatypicalantipsychoticsinolderadults,
11-13 32
and the study by Liperoti et al, which found an increased risk
with haloperidol compared with risperidone in patients with
dementia in nursing homes in five US states (n=9729).
35 Our
findingofareducedriskofdeathfromcausesotherthancancer
with quetiapine is compatible with an observation made by
Rossom et al in a population of predominately male veterans
withdementia.
36Incontrast,Liperotietal,usingMinimumData
Set information to determine drug exposure, did not observe
differences in mortality between individual atypical drugs.
35
Another study that examined causes of death in elderly users
of antipsychotics was done in British Columbia and found that
those who started treatment with conventional rather than
atypical antipsychotics had the highest relative risk of death
from respiratory diseases (hazard ratio 1.71, 1.35 to 2.17),
followed by circulatory disorders (1.23, 1.10 to 1.36).
37 Our
findings for haloperidol compared with risperidone in nursing
home residents in the US mirror these results. Differences in
cause specific mortality with atypical antipsychotic drugs have
not previously been examined. Our comparative findings,
however, are consistent with results reported in a recent
meta-analysisthatcombineddatafromplacebocontrolledtrials
and found that the risk of cardiovascular outcomes in elderly
patients with dementia was increased with risperidone and
olanzapine but not with quetiapine. Likewise, risperidone, but
not olanzapine or quetiapine, was found to be associated with
an increased risk of stroke.
38
Study strengths and weaknesses
Amajorstrengthofourstudyisthelargepopulationofresidents
in US nursing homes, which allowed us to examine the effect
ofindividualdrugs,differentdoses,andcausespecificmortality.
Itwaslargeenoughtoallowustorestrictourpopulationtonew
users, which reduces the likelihood of missing early adverse
events, allows for an evaluation of risks over duration of use,
ensures that the assessment of baseline characteristics is not
influencedbyanyeffectsofantipsychotictreatment,andreduces
the likelihood that current treatment assignment is influenced
bypastexperiencesrelatedtodrugs,suchasadverseeventsand
refractorysymptoms.
17Toclearlyidentifyexposuregroups,we
compared single drug treatments with each other and censored
patient follow-up as soon as the patient switched drugs or
augmented treatment with a second antipsychotic drug.
We looked at residual confounding by indication as an
alternative explanation of our findings. This would occur if
patientswhowerefrailandatincreasedriskofdeathweremore
or less likely to be prescribed certain antipsychotic drugs. We
supplementedconfounderinformationderivedfromclaimsdata
withclinicalassessmentdata(MinimumDataSet)andpotential
indicatorsofnursinghomequality(OnlineSurveyCertification
and Reporting).
39 We used multiple methods to mitigate
confounding by the predefined covariates and by proxies for
unobservedfactors(adjustmentforhighdimensionalpropensity
score
31) and found results to be consistent. Sensitivity analyses
showed that strong risk factors for death that are fairly
imbalanced among exposure groups must be unmeasured and
uncontrolled to explain the observed associations for deaths
from causes other that cancer.
There is potential for misclassification of exposure status
through lack of consumption of filled prescriptions. Patients in
nursing homes are closely monitored, however, and adherence
willbehigh,butoccasionalas-neededusemightbeanimportant
sourceofmisclassification.Patientswereclassifiedintogroups
with low and high doses according to the initial prescription.
In case of dose adjustments, this could have resulted in
misclassification of exposure in dose stratified analyses. Dose
assignment, however, remained unchanged for over 90% of
patients according to the second and last prescription filled
before the end of follow-up. Results were also consistent when
we used an alternative dose conversion algorithm.
40
Broad categories of causes of death identified from death
certificates have been found to agree with causes of death
adjudicated by a physician, but problems arise when more
specificsubcategoriesofdeath—suchasspecificcardiovascular
causes—are used.
22 23 Although we examined only broad
categories of causes of death, potential for misclassification
remains, particularly in elderly people for whom the incidence
of cardiovascular deaths tends to be overestimated,
22 and we
cautionagainstoverinterpretationoftheseaspectsoftheresults.
OurstudypopulationconsistedofpatientseligibleforMedicaid.
This restriction should not affect the validity of our findings.
The central issue determining internal validity is comparability
between the subcohorts included, not whether the study sample
is representative of patients in nursing homes overall. As long
as socioeconomic status and its correlates do not modify the
effectofantipsychoticdrugsonshorttermmortality,thefindings
should also be generalisable (that is, externally valid).
Conclusions and implications
Various environmental, psychosocial, and behavioural
interventions have been developed to deal with behavioural
disturbances in patients with dementia,
41 but their effectiveness
has not been rigorously studied
42 and their implementation is
often hampered by a lack of resources.
43 Although such
non-pharmacological interventions are nearly universally
recommended as first line treatment,
44 they are commonly
insufficient in people with severe and persistent or recurrent
symptoms. Consequently, most patients will be given a
psychotropic drug at some point in their disease progression.
9 16
In the absence of proved effective and safe alternative
pharmacologicaltreatments,itislikelythatantipsychoticdrugs
will continue to be used widely, despite the fact that they have
not been approved for this indication, their use cannot be
justifiedasevidencebased,
38andtherearecleardataconfirming
their associated risk.
The evidence provided in our study reinforces the important
risks associated with the use of these drugs and underscores the
need to try alternative means of dealing with behavioural
problems in older patients with dementia. While our findings
cannot tackle the efficacy-safety trade off involved in the
decisiontoproceedwithdrugtreatmentforsevereandrefractory
behavioural problems in people with dementia, they can
contributetodecisionmakingregardingtreatmentforclinicians
consideringuseofantipsychoticsinpatientswhosebehavioural
problems might themselves pose a risk to the patient or others.
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RESEARCHIf the clinician faces a situation in which use of these drugs
seems inevitable, our findings underscore the importance of
always prescribing the lowest possible dose and of closely
monitoring patients, especially shortly after the start of
treatment. The evidence accumulated so far implies that use of
haloperidol in this vulnerable population cannot be justified
because of the excess harm. Quetiapine might be somewhat
safer than other atypical drugs, but these findings will require
replication in other studies.
Contributors: All authors were responsible for study concept and design.
SC and SS acquired the data, which were analysed and interpreted by
all authors. KFH drafted the manuscript, which was critically revised for
important intellectual content by all authors. KFH, TG, RL, and SS did
the statistical analysis. SC, JA, and SS gave administrative, technical,
or material support. SS was the study supervisor, and KFH is guarantor.
Funding: This study was supported by AHRQ/FDA Award HS017918
and AHRQ Award HS016097. KFH and SS were partially funded by
National Institute of Mental Health R01-MH078708. The funders had
no role in the design and conduct of the study; collection, management,
analysis, and interpretation of the data; and preparation, review, or
approval of the manuscript.
Competing interests: All authors have completed the ICMJE uniform
disclosure form at www.icmje.org/coi_disclosure.pdf (available on
request from the corresponding author) and declare: no support from
any organisation for the submitted work; no financial relationships with
any organisations that might have an interest in the submitted work in
the previous three years; no other relationships or activities that could
appear to have influenced the submitted work.
Ethical approval: This study was approved by the Institutional Review
Board of the Brigham and Women’s Hospital, the Partners Human
Research Committee.
Data sharing: No additional data available.
1 Liperoti R, Mor V, Lapane KL, Pedone C, Gambassi G, Bernabei R. The use of atypical
antipsychotics in nursing homes. J Clin Psychiatry 2003;64:1106-12.
2 Briesacher BA, Limcangco MR, Simoni-Wastila L, Doshi JA, Levens SR, Shea DG, et al.
The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med
2005;165:1280-5.
3 Bronskill SE, Anderson GM, Sykora K, Wodchis WP, Gill S, Shulman KI, et al. Neuroleptic
drug therapy in older adults newly admitted to nursing homes: incidence, dose, and
specialist contact. J Am Geriatr Soc 2004;52:749-55.
4 Rochon PA, Stukel TA, Bronskill SE, Gomes T, Sykora K, Wodchis WP, et al. Variation
in nursing home antipsychotic prescribing rates. Arch Intern Med 2007;167:676-83.
5 Chen Y, Briesacher B, Field T, Tjia J, Lau D, Gurwitz J. Unexplained variation across US
nursing homes in antipsychotic prescribing rates. Arch Intern Med 2010;170:89-95.
6 Beers M, Avorn J, Soumerai S, Everitt D, Sherman D, Salem S. Psychoactive medication
use in intermediate-care facility residents. JAMA 1988;260:3016-20.
7 Ray WA, Federspiel CF, Schaffner W. A study of antipsychotic drug use in nursing homes:
epidemiologic evidence suggesting misuse. Am J Public Health 1980;70:485-91.
8 Avorn J, Wang P. Drug prescribing, adverse reactions, and compliance in elderly patients.
In: Salzman C, ed. Clinical geriatric psychopharmacology. 4th ed. Lippincot, Williams &
Wilkins, 2005:23-47.
9 Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, et al. ACNP White
Paper: update on use of antipsychotic drugs in elderly persons with dementia.
Neuropsychopharmacology 2007;33:957-70.
10 FDA Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioral
disturbances. 2010. www.fda.gov/drugs/drugsafety/
postmarketdrugsafetyinformationforpatientsandproviders/ucm053171.
11 Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of
death in elderly users of conventional vs atypical antipsychotic medications. N Engl J Med
2005;353:2335-41.
12 Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated
with the use of conventional versus atypical antipsychotic drugs among elderly patients.
CMAJ 2007;176:627-32.
13 Gill SS, Bronskill SE, Normand S-LT, Anderson GM, Sykora K, Lam K, et al. Antipsychotic
drug use and mortality in older adults with dementia. Ann Intern Med 2007;146:775-86.
14 FDA. Information for Healthcare Professionals—antipsychotics. 2011. www.fda.gov/Drugs/
DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm.
15 Office of Inspector General, Department of Health and Human Services. Medicare atypical
antipsychotic drug claims for elderly nursing home residents. Department of Health and
Human Services, 2011.
16 Wang P, Brookhart M, Setoguchi S, Patrick A, Schneeweiss S. Psychotropic medication
use for behavioral symptoms of dementia. Curr Neurol Neurosci Rep 2006;6:490-5.
17 Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J
Epidemiol 2003;158:915-20.
18 Schneeweiss S. A basic study design for expedited safety signal evaluation based on
electronic healthcare data. Pharmacoepidemiol Drug Saf 2010;19:858-68.
19 Atkins M, Burgess A, Bottomley C, Riccio M. Chlorpromazine equivalents: a consensus
of opinion for both clinical and research applications. Psychiatr Bull R Coll Psychiatr
1997;21:224-6.
20 Lehman A, Steinwachs D. Translating research into practice: the Schizophrenia Patient
Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull
1998;24:1-10.
21 Woods S. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin
Psychiatry 2003;64:663-7.
22 Sesso H, Gaziano J, Glynn R, Buring J. Value of an endpoints committee versus the use
of nosologists for validating cause of death. Contemp Clin Trials 2006;27:333-9.
23 Chan Y, Pariser S, Neufeld G. Atypical antipsychotics in older adults. Pharmacotherapy
1999;19:811-22.
24 Lawlor B. Behavioral and psychological symptoms in dementia: the role of atypical
antipsychotics. J Clin Psych 2004;65:5-10.
25 Maixner S, Mellow A, Tandon R. The efficacy, safety, and tolerability of antipsychotics in
the elderly. J Clin Psych 1999;60:29-41.
26 Tariot P. The older patient: the ongoing challenge of efficacy and tolerability. J Clin Psych
1999;60:29-33.
27 Alexopoulos G, Streim J, Carpenter D, Docherty J. Expert Consensus Panel for Using
Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients. J Clin
Psych 2004;65:5-99.
28 Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of
comorbidity scores to control for confounding in epidemiologic studies using claims data.
Am J Epidemiol 2001;154:854-64.
29 Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies
using propensity scores. Ann Intern Med 2002;137:693-5.
30 Robins J, Hernán M, Brumback B. Marginal structural models and causal inference in
epidemiology. Epidemiology 2000;11:550-60.
31 Schneeweiss S, Rassen J, Glynn R, Avorn J, Mogun H, Brookhart M. High-dimensional
propensity score adjustment in studies of treatment effects using health care claims data.
Epidemiology 2009;20:512-22.
32 Huybrechts K, Rothman K, Silliman R, Brookhart M, Schneeweiss S. Risk of death and
hospital admission for major medical events after initiation of psychotropic medications
in older adults admitted to nursing homes. CMAJ 2011;183:E411-9.
33 Patorno E, Bohn R, Wahl P, Avorn J, Patrick A, Liu J, et al. Anticonvulsant medications
and the risk of suicide, attempted suicide, or violent death. JAMA 2010;303:1401-9.
34 Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders
in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf
2006;15:291-303.
35 Liperoti R, Onder G, Landi F, Lapane K, Mor V, Bernabei R, et al. All-cause mortality
associated with atypical and conventional antipsychotics among nursing home residents
with dementia: a retrospective cohort study. J Clin Psych 2009;70:1340-7.
36 Rossom R, Rector T, Lederle F, Dysken M. Are all commonly prescribed antipsychotics
associated with greater mortality in elderly male veterans with dementia? J Am Geriatr
Soc 2010;58:1027-34.
37 Setoguchi S, Wang P, Brookhart M, Canning C, Kaci L, Schneeweiss S. Potential causes
of higher mortality in elderly users of conventional and atypical antipsychotic medications.
J Am Geriatr Soc 2008;56:1644-50.
38 Maher A, Maglione M, Bagley S, Suttorp M, Hu J-H, Ewing B, et al. Efficacy and
comparative effectiveness of atypical antipsychotic medications for off-label uses in adults:
a systematic review and meta-analysis. JAMA 2011;306:1359-69.
39 Huybrechts K, Brookhart A, Rothman K, Silliman R, Gerhard T, Crystal S, et al. Comparison
of different approaches to confounding adjustment in a study on the effect of antipsychotic
medication on mortality in older nursing home patients. Am J Epidemiol 2011;174:1089-99.
40 Andreasen N, Pressler M, Nopoulos P, Miller D, Ho B. Antipsychotic dose equivalents
and dose-years: a standardized method for comparing exposure to different drugs. Biol
Psychiatry 2010;67:255-62.
41 Beck C. Psychosocial and behavioral interventions for Alzheimer’s disease patients. Am
J Geriatr Psychiatry 1998;6:S41-8.
42 Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents
with depression or behavioral symptoms associated with dementia: a review of the
literature. J Am Geriatr Soc 2003;51:1305-17.
43 Camp CJ, Cohen-Mansfield J, Capesuti EA. Use of nonpharmacologic interventions
among nursing home residents with dementia. Psychiatr Serv 2002;53:1397-401.
44 Cummings J. Behavioral and neuropsychiatric outcomes in Alzheimer’s disease. CNS
Spectr 2005;10:22-5.
45 Sturmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment effects in the presence of
unmeasured confounding: dealing with observations in the tails of the propensity score
distribution—a simulation study. Am J Epidemiol 2010;172:843-54.
Accepted: 29 December 2011
Cite this as: BMJ 2012;344:e977
This is an open-access article distributed under the terms of the Creative Commons
Attribution Non-commercial License, which permits use, distribution, and reproduction in
any medium, provided the original work is properly cited, the use is non commercial and
is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-
nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e977 doi: 10.1136/bmj.e977 (Published 23 February 2012) Page 5 of 12
RESEARCHWhat is already known on this topic
Both typical and atypical antipsychotics carry a black box warning of an increased risk of death in elderly patients with behavioural
symptoms associated with dementia
Despite their known risks and the absence of compelling efficacy data, these drugs are still used widely in this population
Little is known about whether different drugs differ in their mortality risk
What this study adds
In a large cohort of elderly patients in nursing homes, antipsychotic drugs conferred a dose related risk of death: compared with
risperidone, haloperidol users had an increased risk and quetiapine users a decreased risk
The effects were strongest shortly after the start of treatment and remained after adjustment for dose
Though extensive measures were taken to mitigate confounding, and findings were consistent in sensitivity and confirmatory analyses,
they should be confirmed with other data sources
Tables
Table 1| Selected characteristics in residents starting antipsychotic drugs during stay in nursing home. Figures are numbers (percentage)
or means
Ziprasidone
(n=1061)
Risperidone (n=27
936)
Quetiapine (n=15
776)
Olanzapine (n=22
919)
Aripiprazole
(n=1849)
Haloperidol
(n=5904)
630/924 (68.2) 2498/25 033 (10.0) 7376/14 694 (50.2) 9461/21 296 (44.4) 1501/1739 (86.3) 2056/3507 (58.6) High dose*
Region:
47 (4.4) 4577 (16.4) 2801 (17.8) 3816 (16.6) 332 (18.0) 648 (11.0) Northeast
253 (23.8) 8749 (31.3) 4430 (28.1) 6582 (28.7) 607 (32.8) 1904 (32.2) Midwest
695 (65.5) 11 419 (40.9) 6952 (44.1) 8976 (39.2) 764 (41.3) 2531 (42.9) South
66 (6.2) 3191 (11.4) 1593 (10.1) 3545 (15.5) 146 (7.9) 821 (13.9) West
512 (48.3) 9938 (35.6) 4753 (30.1) 7255 (31.7) 519 (28.1) 2508 (42.5) Rural (v urban) setting
Demographics:
302 (28.5) 6858 (24.5) 4028 (25.5) 5555 (24.2) 508 (27.5) 1659 (28.1) Male
82.6 83.7 83.0 83.5 81.9 83.8 Mean age (years)
851 (80.2) 22 983 (82.3) 13 015 (82.5) 18 969 (82.8) 1473 (79.7) 4730 (80.1) White race
Psychiatric morbidity:
655 (61.7) 16 899 (60.5) 9668 (61.3) 13 418 (58.5) 1164 (63.0) 3281 (55.6) Dementia
371 (35.0) 7900 (28.3) 5251 (33.3) 6915 (30.2) 701 (37.9) 1407 (23.8) Depression
45 (4.2) 811 (2.9) 524 (3.3) 752 (3.3) 42 (2.3) 168 (2.8) Anxiety
93 (8.8) 1705 (6.1) 1169 (7.4) 1315 (5.7) 132 (7.1) 373 (6.3) Delirium
165 (15.6) 3053 (10.9) 1800 (11.4) 2400 (10.5) 244 (13.2) 623 (10.6) Psychotic disorder
Impairment in cognitive function:
180 (17.0) 4049 (14.5) 2331 (14.8) 3578 (15.6) 330 (17.8) 846 (14.3) Intact to moderate
616 (58.1) 15 960 (57.1) 8963 (56.8) 13 036 (56.9) 1093 (59.1) 3252 (55.1) Moderate to severe
265 (25.0) 7927 (28.4) 4482 (28.4) 6305 (27.5) 426 (23.0) 1806 (30.6) Severe to very severe
41 (3.9) 1050 (3.8) 575 (3.6) 848 (3.7) 87 (4.7) 190 (3.2) Delusions
157 (14.8) 4119 (14.7) 2154 (13.7) 3317 (14.5) 270 (14.6) 810 (13.7) Verbally or physically
abusive behaviour
284 26.8) 7385 (26.4) 4039 (25.6) 5908 (25.8) 453 (24.5) 1512 (25.6) Non-aggressive
behavioural problems
Cardiovascular morbidity:
48 (4.5) 1587 (5.7) 811 (5.1) 1197 (5.2) 85 (4.6) 417 (7.1) Myocardial infarction
236 (22.2) 6613 (23.7) 3674 (23.3) 5262 (23.0) 373 (20.2) 1617 (27.4) Arrhythmias
51 (4.8) 1236 (4.4) 626 (4.0) 1046 (4.6) 74 (4.0) 297 (5.0) Ischaemic heart disease
748 (70.5) 18 129 (64.9) 10 439 (66.2) 14 413 (62.9) 1262 (68.3) 3897 (66.0) Hypertension
362 (34.1) 9057 (32.4) 5015 (31.8) 7107 (31.0) 562 (30.4) 2286 (38.7) Congestive heart failure
309 (29.1) 7868 (28.2) 4546 (28.8) 6445 (28.1) 532 (28.8) 1752 (29.7) Cerebrovascular disease
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RESEARCHTable 1 (continued)
Ziprasidone
(n=1061)
Risperidone (n=27
936)
Quetiapine (n=15
776)
Olanzapine (n=22
919)
Aripiprazole
(n=1849)
Haloperidol
(n=5904)
Other comorbidities:
266 (25.1) 6656 (23.8) 3918 (24.8) 4699 (20.5) 536 (29.0) 1482 (25.1) Diabetes
66 (6.2) 1187 (4.2) 1525 (9.7) 1132 (4.9) 112 (6.1) 270 (4.6) Parkinson’s disease
Functional impairment:
445 (41.9) 11 211 (40.1) 6055 (38.4) 9222 (40.2) 777 (42.0) 2153 (36.5) Independent, supervision,
or limited
561 (52.9) 15 509 (55.5) 8982 (56.9) 12 715 (55.5) 1012 (54.7) 3403 (57.6) Dependence or extensive
55 (5.2) 1216 (4.4) 739 (4.7) 982 (4.3) 60 (3.2) 348 (5.9) Total dependence
General indicators of comorbidity:
3.1 3.1 3.1 3.0 3.2 3.3 Mean Charlson index†
15.3 14.4 15.0 14.3 15.0 15.9 Mean No of prescription
drugs received
1.1 0.9 0.9 0.9 0.8 1.1 Mean No of outpatient
visits
20.6 18.0 17.7 17.9 15.3 20.0 Mean No of days in
hospital
History of prescriptions:
716 (67.5) 18 502 (66.2) 11 362 (72.0) 15 863 (69.2) 1351 (73.1) 3617 (61.3) Antidepressants
485 (45.7) 12 570 (45.0) 7623 (48.3) 10 493 (45.8) 802 (43.4) 3042 (51.5) Hypnotic agents
149 (14.0) 3335 (11.9) 2202 (14.0) 3078 (13.4) 283 (15.3) 656 (11.1) Other psychoactive
agents‡
438 (41.3) 9163 (32.8) 5742 (36.4) 6982 (30.5) 766 (41.4) 1496 (25.3) Dementia drug
*>50 mg chlorpromazine equivalents, in subset of patients receiving tablets or caplets.
†Individual comorbidities defined based on at least one admission to hospital or at least one outpatient visit with respective ICD codes.
‡Includes barbiturate, non-benzodiazepine anxiolytic, stimulant/ADHD drug, lithium, valproate, carbamazepine, lamotrigine.
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RESEARCHTable 2| Death within 180 days after start of treatment with antipsychotic drugs* in elderly patients in nursing homes
Ziprasidone
(n=1061; 235)
Risperidone (n=27
936; 6720 person
years)
Quetiapine (n=15
776; 3945 person
years)
Olanzapine (n=22
919; 5741 person
years)
Aripiprazole
(n=1849; 465
person years)
Haloperidol
(n=5904;683person
years)
Rate (95%
CI) No
Rate (95%
CI) No
Rate (95%
CI) No
Rate (95%
CI) No
Rate (95%
CI) No
Rate (95%
CI) No
31.1 (24.4
to 38.6)
73 36.2 (34.8
to 37.7)
2434 28.4 (26.8
to 30.1)
1120 36.7 (35.1
to 38.2)
2104 26.2 (21.8
to 31.1)
122 109.1 (101.4
to 117.0)
745 All non-cancer
mortality
Cause specific mortality:
15.8 (11.1
to 21.2)
37 18.3 (17.3
to 19.3)
1230 13.7 (12.6
to 14.9)
542 18.2 (17.1
to 19.3)
1045 12.3 (9.3 to
15.6)
57 51.4 (46.2 to
56.9)
351 Circulatory
system
4.7 (2.3 to
7.9)
11 3.9 (3.5 to
4.4)
263 2.6 (2.1 to
3.1)
102 3.3 (2.9 to
3.8)
192 1.3 (0.5 to
2.5)
6 11.9 (9.4 to
14.6)
81 Cerebrovascular
diseases
5.5 (2.9 to
9.0)
13 5.1 (4.6 to
5.6)
342 3.8 (3.2 to
4.5)
151 5.6 (5.0 to
6.2)
320 5.6 (3.6 to
7.9)
26 18.9 (15.8 to
22.3)
129 Respiratory
system
9.8 (6.2 to
14.2)
23 12.8 (12.0
to 13.7)
862 10.8 (9.8 to
11.9)
427 12.9 (12.0
to 13.8)
739 8.4 (6.0 to
11.2)
39 38.8 (34.3 to
43.6)
265 Other
*Rate expressed per 100 person years.
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RESEARCHTable 3| Hazard ratios (95% CI) for death in elderly people in nursing homes within 180 days of start of treatment with various antipsychotic
drugs
HR (95% CI)
No of events
Adjusted for high
dimensional propensity
score*
Adjusted for propensity
score*
Adjusted for age, sex, and
calendar year Unadjusted
Non-cancer mortality
1.81 (1.65 to 1.98) 2.07 (1.89 to 2.26) 2.37 (2.17 to 2.59) 2.42 (2.21 to 2.65) 745 Haloperidol
0.95 (0.78 to 1.15) 0.88 (0.73 to 1.07) 0.77 (0.64 to 0.93) 0.76 (0.63 to 0.92) 122 Aripiprazole
1.01 (0.95 to 1.08) 1.02 (0.96 to 1.08) 1.03 (0.97 to 1.09) 1.01 (0.95 to 1.07) 2104 Olanzapine
0.83 (0.77 to 0.89) 0.81 (0.75 to 0.88) 0.80 (0.75 to 0.87) 0.80 (0.74 to 0.86) 1120 Quetiapine
0.90 (0.69 to 1.17) 0.92 (0.72 to 1.17) 0.90 (0.70 to 1.14) 0.88 (0.69 to 1.12) 73 Ziprasidone
Cause specific mortality
Circulatory system:
1.66 (1.46 to 1.90) 1.86 (1.63 to 2.12) 2.21 (1.94 to 2.51) 2.25 (1.98 to 2.56) 351 Haloperidol
0.92 (0.69 to 1.22) 0.84 (0.64 to 1.11) 0.75 (0.57 to 0.98) 0.71 (0.54 to 0.93) 57 Aripiprazole
1.00 (0.92 to 1.09) 1.01 (0.92 to 1.10) 1.00 (0.92 to 1.09) 1.00 (0.92 to 1.09) 1045 Olanzapine
0.84 (0.75 to 0.93) 0.81 (0.72 to 0.89) 0.79 (0.71 to 0.88) 0.77 (0.70 to 0.86) 542 Quetiapine
0.91 (0.64 to 1.31) 0.89 (0.63 to 1.26) 0.89 (0.63 to 1.26) 0.85 (0.6 to 1.21) 37 Ziprasidone
Cerebrovascular diseases:
1.95 (1.48 to 2.58) 2.23 (1.71 to 2.90) 2.56 (1.97 to 3.33) 2.59 (2.00 to 3.37) 81 Haloperidol
0.43 (0.18 to 1.06) 0.34 (0.14 to 0.82) 0.31 (0.13 to 0.76) 0.30 (0.12 to 0.72) 6 Aripiprazole
0.83 (0.68 to 1.01) 0.88 (0.73 to 1.07) 0.87 (0.72 to 1.06) 0.88 (0.72 to 1.06) 192 Olanzapine
0.73 (0.57 to 0.93) 0.67 (0.53 to 0.86) 0.68 (0.54 to 0.87) 0.66 (0.52 to 0.84) 102 Quetiapine
1.01 (0.47 to 2.17) 1.03 (0.50 to 2.10) 1.05 (0.52 to 2.12) 0.98 (0.48 to 1.98) 11 Ziprasidone
Respiratory system:
1.99 (1.57 to 2.51) 2.53 (2.02 to 3.18) 3.01 (2.41 to 3.76) 3.06 (2.45 to 3.82) 129 Haloperidol
1.36 (0.90 to 2.07) 1.29 (0.85 to 1.97) 1.07 (0.70 to 1.63) 1.11 (0.73 to 1.68) 26 Aripiprazole
1.00 (0.85 to 1.17) 1.05 (0.89 to 1.23) 1.08 (0.93 to 1.27) 1.07 (0.91 to 1.25) 320 Olanzapine
0.70 (0.57 to 0.86) 0.76 (0.62 to 0.93) 0.74 (0.61 to 0.90) 0.76 (0.63 to 0.93) 151 Quetiapine
1.03 (0.56 to 1.89) 1.19 (0.66 to 2.13) 1.12 (0.63 to 2.00) 1.14 (0.64 to 2.03) 13 Ziprasidone
Other:
1.95 (1.67 to 2.28) 2.19 (1.88 to 2.55) 2.36 (2.04 to 2.74) 2.42 (2.09 to 2.80) 265 Haloperidol
0.77 (0.54 to 1.10) 0.78 (0.56 to 1.09) 0.69 (0.50 to 0.96) 0.70 (0.50 to 0.96) 39 Aripiprazole
1.03 (0.92 to 1.14) 1.02 (0.92 to 1.13) 1.04 (0.94 to 1.15) 1.01 (0.91 to 1.12) 739 Olanzapine
0.84 (0.74 to 0.95) 0.85 (0.75 to 0.95) 0.84 (0.75 to 0.95) 0.85 (0.75 to 0.96) 427 Quetiapine
0.78 (0.48 to 1.26) 0.86 (0.56 to 1.31) 0.81 (0.53 to 1.24) 0.82 (0.54 to 1.25) 23 Ziprasidone
*Models stratified across 10th of propensity score, after truncating 2.5% of patients on either extreme of propensity score distribution in each exposure pairing to
avoid bias from inclusion of people with propensity score from outside shared range of scores.
45
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RESEARCHFigures
Fig 1 Assembly of study cohort of patients in nursing homes starting treatment with antipsychotic drugs (ICD-9=international
classification of diseases, ninth revision; MDS=Minimum Data Set; OSCAR=Online Survey Certification and Reporting)
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e977 doi: 10.1136/bmj.e977 (Published 23 February 2012) Page 10 of 12
RESEARCHFig 2 Adjusted Kaplan-Meier plots for death from causes other than cancer. Each participant is weighed by inverse of his
or her probability for treatment as estimated in multivariate propensity score analysis
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RESEARCHFig 3 Hazard ratios (adjusted for propensity score) for death from causes other than cancer by dose of various antipsychotic
drugs compared with similar dose of risperidone (restricted to users of tablets or caplets). Results for aripiprazole and
ziprasidone not presented because of small numbers of events in some dose groups
Fig 4 Hazard ratios (adjusted propensity score) for death from causes other than cancer by dose of various antipsychotic
drugs with low dose group of each drug as reference. Results for aripiprazole and ziprasidone not presented because of
small numbers of events in some dose groups
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